X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (45510) 45510
Newsletter (4009) 4009
Publication (3382) 3382
Newspaper Article (1411) 1411
Magazine Article (422) 422
Book Review (411) 411
Book Chapter (93) 93
Conference Proceeding (76) 76
Trade Publication Article (55) 55
Transcript (39) 39
Dissertation (18) 18
Data Set (13) 13
Book / eBook (12) 12
Reference (8) 8
Paper (4) 4
Web Resource (3) 3
Journal / eJournal (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32923) 32923
male (23678) 23678
hypoglycemic agents - therapeutic use (22815) 22815
index medicus (22622) 22622
female (18864) 18864
diabetes mellitus, type 2 - drug therapy (15468) 15468
diabetes (15181) 15181
animals (13240) 13240
middle aged (13037) 13037
hypoglycemic agents (12935) 12935
endocrinology & metabolism (12677) 12677
type 2 diabetes (11477) 11477
hypoglycemic agents - pharmacology (11360) 11360
hypoglycemic agents - administration & dosage (11155) 11155
insulin (10217) 10217
adult (10119) 10119
blood glucose - metabolism (10091) 10091
aged (9039) 9039
glucose (8081) 8081
diabetes therapy (7680) 7680
insulin - therapeutic use (7364) 7364
rats (7345) 7345
diabetes mellitus, type 2 - blood (7057) 7057
pharmacology & pharmacy (6770) 6770
hypoglycemic agents - adverse effects (6077) 6077
blood glucose - drug effects (5988) 5988
research (5736) 5736
insulin - administration & dosage (5686) 5686
treatment outcome (5634) 5634
care and treatment (5181) 5181
diabetes mellitus (5159) 5159
metformin (5041) 5041
insulin resistance (5010) 5010
risk factors (4939) 4939
blood glucose - analysis (4877) 4877
mellitus (4828) 4828
drug therapy (4654) 4654
analysis (4606) 4606
mice (4547) 4547
diabetes mellitus, type 1 - drug therapy (4403) 4403
glycemic control (4361) 4361
hyperglycemia (4279) 4279
blood sugar (4185) 4185
glycated hemoglobin a - metabolism (4044) 4044
insulin - blood (3861) 3861
metformin - therapeutic use (3750) 3750
dextrose (3506) 3506
diabetes mellitus - drug therapy (3428) 3428
diabetes mellitus, experimental - drug therapy (3406) 3406
medicine, general & internal (3376) 3376
hypoglycemia (3326) 3326
diabetes mellitus, type 2 - complications (3293) 3293
health aspects (3269) 3269
glycated hemoglobin a - analysis (3166) 3166
time factors (3131) 3131
adolescent (3067) 3067
obesity (3032) 3032
therapy (3003) 3003
drug therapy, combination (2991) 2991
diabetics (2805) 2805
rats, wistar (2738) 2738
internal medicine (2676) 2676
dose-response relationship, drug (2664) 2664
insulin-resistance (2642) 2642
risk (2603) 2603
diabetes mellitus, type 1 - blood (2554) 2554
diabetes mellitus, type 2 - metabolism (2531) 2531
administration, oral (2455) 2455
mortality (2373) 2373
hypoglycemia - chemically induced (2313) 2313
hypoglycemic agents - pharmacokinetics (2305) 2305
type 1 diabetes (2304) 2304
insulin - metabolism (2293) 2293
blood glucose (2240) 2240
medical research (2220) 2220
double-blind method (2180) 2180
body mass index (2173) 2173
management (2151) 2151
medicine & public health (2147) 2147
metabolism (2147) 2147
young adult (2098) 2098
insulin - pharmacology (2090) 2090
hypoglycemic agents - chemistry (2080) 2080
glucose metabolism (2070) 2070
chemistry, medicinal (2059) 2059
diabetes mellitus, type 2 - physiopathology (2059) 2059
retrospective studies (2057) 2057
dosage and administration (2044) 2044
physiological aspects (2003) 2003
clinical trials (1975) 1975
glucose tolerance test (1968) 1968
complications (1951) 1951
thiazolidinediones (1937) 1937
oxidative stress (1935) 1935
hyperglycemia - drug therapy (1930) 1930
rats, sprague-dawley (1915) 1915
type 2 diabetes mellitus (1888) 1888
abridged index medicus (1876) 1876
medicine, experimental (1871) 1871
thiazolidinediones - therapeutic use (1862) 1862
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (48709) 48709
German (754) 754
French (401) 401
Chinese (295) 295
Spanish (233) 233
Russian (229) 229
Japanese (187) 187
Italian (167) 167
Hungarian (73) 73
Czech (69) 69
Polish (63) 63
Dutch (61) 61
Portuguese (56) 56
Swedish (31) 31
Danish (25) 25
Norwegian (23) 23
Ukrainian (16) 16
Serbian (12) 12
Finnish (11) 11
Korean (11) 11
Hebrew (10) 10
Croatian (7) 7
Romanian (7) 7
Turkish (5) 5
Bulgarian (4) 4
Icelandic (4) 4
Lithuanian (4) 4
Slovak (4) 4
Bosnian (1) 1
Indonesian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2013, Volume 15, Issue 11, pp. 1040 - 1048
Aims Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady‐state liraglutide 1.8 mg... 
antidiabetic drug | lipid‐lowering therapy | GLP‐1 analogue | phase I‐II study | type II diabetes | randomized trial | Type II diabetes | Randomized trial | Antidiabetic drug | Lipid-lowering therapy | GLP-1 analogue | Phase I-II study | LIPEMIA | OXIDATIVE STRESS | RECEPTOR AGONISTS | EXENATIDE | ACID BREATH TEST | INSULIN RESPONSES | MELLITUS | lipid-lowering therapy | phase I-II study | THERAPY | GLUCOSE | ENDOCRINOLOGY & METABOLISM | GLUCAGON | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diet, High-Fat - adverse effects | Half-Life | Glucagon-Like Peptide 1 - blood | Male | Hypoglycemic Agents - blood | Cardiovascular Diseases - complications | Hypolipidemic Agents - blood | Lipids - blood | Postprandial Period | Cardiovascular Diseases - epidemiology | Female | Glucagon-Like Peptide 1 - pharmacokinetics | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hypolipidemic Agents - adverse effects | Hypoglycemic Agents - pharmacokinetics | Double-Blind Method | Glucagon-Like Peptide 1 - analogs & derivatives | Obesity - complications | Risk Factors | Hyperlipidemias - prevention & control | Germany - epidemiology | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Gastric Emptying - drug effects | Hyperlipidemias - etiology | Denmark - epidemiology | Aged | Hypolipidemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypolipidemic Agents - pharmacokinetics | Hypoglycemic Agents - adverse effects | Liraglutide | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Low density lipoproteins | Anticholesteremic agents | Clinical trials | Triglycerides | Glucose | Fatty acids | Cholesterol | Dextrose | Glucose metabolism | Hypoglycemic agents | Diabetes therapy | Lipids | Diet | Apolipoproteins
Journal Article
Journal Article
Journal Article
Journal Article
Annals of Surgery, ISSN 0003-4932, 08/2013, Volume 258, Issue 2, pp. 262 - 269
OBJECTIVE:We conducted a pharmacokinetic (PK) study and a pharmacodynamic (PD) study to assess whether Roux-en-Y gastric bypass (RYGB) surgery is associated... 
furosemide | oral cocktail | CYP3A | gastric bypass | drug metabolism | SURGERY | FATTY LIVER-DISEASE | WEIGHT-LOSS | TRENDS | P-GLYCOPROTEIN | OBESITY | INTESTINAL ADAPTATION | BARIATRIC SURGERY | ABSORPTION | HEPATIC STEATOSIS | Gastric Bypass | Diuretics - pharmacokinetics | Excitatory Amino Acid Antagonists - pharmacokinetics | Humans | Middle Aged | Tolbutamide - urine | Male | Caffeine - pharmacokinetics | Midazolam - urine | Anti-Ulcer Agents - pharmacokinetics | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Diuretics - urine | Diuretics - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Furosemide - pharmacokinetics | Omeprazole - administration & dosage | Excitatory Amino Acid Antagonists - administration & dosage | Hypoglycemic Agents - urine | Omeprazole - urine | Central Nervous System Stimulants - pharmacokinetics | Midazolam - blood | Dextromethorphan - urine | Adolescent | GABA Modulators - urine | Central Nervous System Stimulants - urine | Dextromethorphan - administration & dosage | Furosemide - administration & dosage | Tolbutamide - administration & dosage | Tolbutamide - pharmacokinetics | Caffeine - administration & dosage | Omeprazole - blood | GABA Modulators - pharmacokinetics | Midazolam - administration & dosage | Anti-Ulcer Agents - blood | Chromatography, High Pressure Liquid | Case-Control Studies | Excitatory Amino Acid Antagonists - urine | Hypoglycemic Agents - blood | Tandem Mass Spectrometry | Biotransformation | Adult | Female | Dextromethorphan - pharmacokinetics | Furosemide - urine | Caffeine - urine | Caffeine - blood | GABA Modulators - administration & dosage | GABA Modulators - blood | Omeprazole - pharmacokinetics | Anti-Ulcer Agents - urine | Midazolam - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Dextromethorphan - blood | Excitatory Amino Acid Antagonists - blood | Tolbutamide - blood | Aged | Central Nervous System Stimulants - blood | Pharmacokinetics | Central Nervous System Stimulants - administration & dosage
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2015, Volume 17, Issue 4, pp. 414 - 422
Aim To describe the clinical effects of single and multiple doses of a potent, selective, orally administered, small‐molecule antagonist of the human glucagon... 
pharmacokinetics | diabetes care | glucagon antagonist | pharmacology | Pharmacology | Glucagon antagonist | Pharmacokinetics | Diabetes care | HYPERGLUCAGONEMIA | MELLITUS | KNOCKOUT MICE | INSULIN | OBESITY | GLUCONEOGENESIS | ALPHA CELL HYPERPLASIA | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | PLASMA-GLUCOSE | Glycated Hemoglobin A - analysis | Single-Blind Method | Hypoglycemia - epidemiology | Receptors, Glucagon - antagonists & inhibitors | Humans | Middle Aged | Half-Life | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Biphenyl Compounds - therapeutic use | Glucagon - blood | Glucagon - agonists | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Hypoglycemic Agents - blood | Hypoglycemic Agents - administration & dosage | Adult | Female | Biphenyl Compounds - blood | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Biphenyl Compounds - pharmacokinetics | Hypoglycemic Agents - pharmacokinetics | Molecular Targeted Therapy - adverse effects | Double-Blind Method | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Biphenyl Compounds - administration & dosage | Aged | Glucagon - secretion | Diabetes Mellitus, Type 2 - drug therapy | Cohort Studies | Type 2 diabetes | Glucagon | Blood sugar | Low density lipoproteins | Fasting | Diabetes | Glucose
Journal Article
HEALTH TECHNOLOGY ASSESSMENT, ISSN 1366-5278, 07/2010, Volume 14, Issue 36, pp. 1 - 1
In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of... 
DRUG-NAIVE PATIENTS | PROTAMINE HAGEDORN INSULIN | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | ORAL HYPOGLYCEMIC AGENTS | GLUCAGON-LIKE PEPTIDE-1 | METFORMIN-TREATED PATIENTS | IMPROVES GLYCEMIC CONTROL | BEDTIME NPH INSULIN | HEALTH CARE SCIENCES & SERVICES | BETA-CELL FUNCTION | CARDIOVASCULAR RISK-FACTORS | Insulin - economics | Nitriles - economics | State Medicine | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Pyrazines - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - economics | Pyrrolidines - therapeutic use | Peptides - economics | Thiazolidinediones - therapeutic use | Triazoles - economics | Adamantane - therapeutic use | Adamantane - economics | Insulin - analogs & derivatives | Sitagliptin Phosphate | Adamantane - analogs & derivatives | Pyrazines - economics | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Insulin, Long-Acting | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - economics | Thiazolidinediones - economics | United Kingdom | Pyrrolidines - economics | Randomized Controlled Trials as Topic | Insulin Glargine | Cost-Benefit Analysis | Venoms - therapeutic use | Quality of Life | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - therapeutic use | Peptides - therapeutic use | Nitriles - therapeutic use
Journal Article
Journal Article